GlassScriptPhysician profile
Edward W Haga
NPI 1245295195
$2,873.36
in general payments reported to CMS, 2019-2025
28 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $513 · 2021: $588 · 2022: $856 · 2023: $407 · 2024: $52.56 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $500.07 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.57 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $246.11 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $221.96 | 2020-2022 | |
| Abbott Laboratories | $177.32 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $165.09 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $151.85 | 2019-2022 | |
| Grifols USA, LLC | $131.22 | 2019-2022 | |
| Eisai INC. | $127.18 | 2020-2021 | |
| Exact Sciences Corporation | $125.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $115.75 | 2020-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $109.82 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.56 | 2020-2022 | |
| Lundbeck LLC | $92.06 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.00 | 2022-2023 | Xifaxan, Trulance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.28 | 2022-2023 | |
| Boston Scientific Corporation | $32.94 | 2025 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $28.96 | 2022 | |
| Photonicare INC | $28.19 | 2025 | Otosight Middle Ear Scope |
| Medtronic, INC. | $27.24 | 2022 | |
| Genentech USA, INC. | $25.76 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $25.60 | 2019 | |
| Amarin Pharma, INC. | $23.86 | 2020-2021 | |
| Astellas Pharma US INC | $20.25 | 2023 | Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $16.46 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $13.85 | 2022 | |
| Aytu Biopharma, INC. | $13.49 | 2020 | |
| Esperion Therapeutics, INC. | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Haga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.